Enbrel — Medical Mutual
Spondyloarthritis (SpA), Other Subtypes
Initial criteria
- Patient age > 18 years
 - If peripheral arthritis, patient has tried ≥1 DMARD OR If axial SpA, objective signs of inflammation shown by elevated CRP OR MRI
 - Medication prescribed by or in consultation with rheumatologist
 - Site of care medical necessity is met
 
Reauthorization criteria
- Patient established on therapy ≥ 6 months
 - Beneficial clinical response per objective measure (e.g., ASDAS, CRP, ESR) OR improved symptoms (pain, stiffness, function)
 - Site of care medical necessity is met
 
Approval duration
initial 6 months, reauth 1 year